Metabolic Bariatric Surgery for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Scoping Review of Biomarker and Histology Changes

被引：0
|
作者：
Shah, A. [1 ]
Mohammadi, A. [3 ]
Haq, A. [4 ]
Walji, D. [5 ]
Zevin, B. [2 ]
机构：
[1] Queens Univ, Med, Kingston, ON, Canada
[2] Queens Univ, Dept Surg, Kingston, ON, Canada
[3] Toronto Metropolitan Univ, Toronto, ON, Canada
[4] Queens Univ, Kingston, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
来源：
JOURNAL OF INVESTIGATIVE MEDICINE | 2025年 / 73卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
251
引用
收藏
页码：297 / 299
页数：3
相关论文
共 50 条
  • [21] Resmetirom and Bariatric Surgery: New Frontiers in Treating Obesity-Related Metabolic Dysfunction-Associated Steatohepatitis
    Au, Kahei
    Yang, Wah
    OBESITY SURGERY, 2024, 34 (09) : 3525 - 3526
  • [22] Expanding the armamentarium for metabolic dysfunction-associated steatohepatitis
    Francque, Sven M.
    Vonghia, Luisa
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (12): : 1066 - 1067
  • [23] Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2024, 66 (1701):
  • [24] Prediction of metabolic dysfunction-associated steatohepatitis resolution
    Loomba, Rohit
    Amangurbanova, Maral
    Bettencourt, Ricki
    Madamba, Egbert
    Siddiqi, Harris
    Richards, Lisa
    Gottwald, Mildred D.
    Feng, Shibao
    Margalit, Maya
    Huang, Daniel
    JOURNAL OF HEPATOLOGY, 2024, 80 : S522 - S523
  • [25] New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024
    Wong, Shu Wei
    Yang, Yong-yu
    Chen, Hui
    Xie, Li
    Shen, Xi-zhong
    Zhang, Ning-ping
    Wu, Jian
    ACTA PHARMACOLOGICA SINICA, 2025,
  • [26] Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
    Bernhard, Johannes
    Galli, Lukas
    Speidl, Walter S.
    Krychtiuk, Konstantin A.
    CURRENT CARDIOLOGY REPORTS, 2025, 27 (01)
  • [27] Tirzepatide for treatment of metabolic dysfunction-associated steatohepatitis: relationship between metabolic and histological responses
    Caussy, C.
    Hartman, M. L.
    Thomas, M. K.
    Mather, K. J.
    Tang, Y.
    Loomba, R.
    Sanyal, A. J.
    DIABETOLOGIA, 2024, 67 : S121 - S121
  • [28] Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
    Eskridge, Wayne
    Cryer, Donna R.
    Schattenberg, Joern M.
    Gastaldelli, Amalia
    Malhi, Harmeet
    Allen, Alina M.
    Noureddin, Mazen
    Sanyal, Arun J.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [29] UNVEILING THE HIDDEN CONNECTION: EXPLORING THE INTERPLAY BETWEEN PERICARDITIS AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
    Ramirez, Lisnaldy
    Garzon-Siatoya, Wendy
    Aloum, Khalid
    Forlemu, Arnold Nongmoh
    Bandaru, Praneeth
    Ciobanu, Camelia
    Wakil, Ali
    Forlemu, Raissa Nana Sede Mbakop
    Krishna, Vura Naga Venkata Rama
    Sharma, Neha
    HEPATOLOGY, 2024, 80 : S472 - S472
  • [30] ECONOMIC COST OF INACTION FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN GERMANY, JAPAN, AND THE UNITED STATES
    Younossi, Zobair
    Tacke, Frank
    Schattenberg, Joern
    Roden, Michael
    Lazarus, Jeffrey
    Allen, Alina
    Cusi, Kenneth
    Eguchi, Yuichiro
    Takahashi, Hirokazu
    Kawaguchi, Takumi
    Wong, Vincent
    Mark, Henry
    Brachowicz, Nicolai
    Henry, Linda
    Nader, Fatema
    Paik, James
    HEPATOLOGY, 2024, 80 : S816 - S817
12345